GlobeNewswire Inc | Oct 28, 2020 04:05PM EDT

October 28, 2020

Third Quarter Highlights:

-- Consolidated Net Revenue of $12.5 Million Up 25% vs. Second Quarter 2020 -- U.S. Net Revenue of $7.0 Million Up 106% vs. Second Quarter 2020 -- Consolidated Net Revenue Down 3%vs.Third Quarter 2019 -- International Net Revenue Up31%vs.Third Quarter 2019 -- Net Loss of ($0.6) Million vs. ($3.1) Million in Third Quarter 2019 -- Adjusted EBITDA of $1.4 Million vs. Negative $(0.5) Million Adjusted EBITDAin Third Quarter 2019

ATLANTA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the third quarter of 2020. Alimera will host a conference call on Thursday, October 29, 2020 at 9:00AM ET to review these financial results and provide an update on corporate developments.

Our strategy to retain our entire work force through the COVID-19 pandemic is paying off as we were able to drive a 25% sequential increase in global net revenue over the second quarter of 2020 and maintain sales through the first nine months of 2020 despite the challenges of the current environment, said Rick Eiswirth, Alimeras President and Chief Executive Officer. Importantly, we are achieving our goal of delivering positive adjusted EBITDA, reporting $1.4million for the third quarter and $2.4 million year to date.

Mr. Eiswirth continued, During this challenging year we are continuing to invest in ILUVIEN and to expand geographically to fuel our significant international growth. In the third quarter we initiated the NEW DAY study, our landmark clinical trial that we believe has the potential to position ILUVIEN as the preferred first-line treatment for diabetic macular edema, and we entered into partnerships to make ILUVIEN available in six additional countries in the future.

Third Quarter 2020 Financial Results

Net RevenueConsolidated net revenue for Q3 2020 was down 3% to $12.5 million, compared to $12.9 million for Q3 2019, and up 25% over Q2 2020.

U.S. net revenue was $7.0 million for Q3 2020, down 20% from $8.7 million during the same period in 2019 but was up 106% over Q2 2020. End user demand, which represents units purchased by physicians and pharmacies from Alimeras U.S. distributors, was 728 units in Q3 2020 compared to 973 units in Q3 2019, a decrease of 25%, but up sequentially from 625 units in Q2 2020, as some recovery from the COVID-19 impact was realized.

The difference between GAAP revenue and end user demand in the U.S. is due to the timing of distributor purchases from quarter to quarter. In both Q3 2020 and Q3 2019, Alimeras distributors purchased more units than they sold to end users, increasing their stock on hand during that quarter. Distributors purchased approximately 19% and 9% more units than they sold to end users in Q3 2020 and Q3 2019, respectively.

International net revenue increased 31% to approximately $5.5 million in Q3 2020, compared to approximately $4.2 million for the same period during 2019, primarily as a result of increased sales in the markets where we sell direct. These direct sales included sales revenue for our posterior uveitis indication.

Operating ExpensesTotal operating expenses for Q3 2020 decreased by $2.5 million or 19% to $10.5million, compared to $13.0 million during Q3 2019. Alimera achieved major expense reductions by reducing travel costs, decreasing attendance at medical conferences that were cancelled or converted to virtual meetings and reducing its spending on external commercial and medical affairs activities. Additionally, Alimera benefitted from a one-time favorable impact of approximately $400,000 associated with recovery of previously paid VAT expense in Germany for the years 2014 through 2018.

Net Loss and Non-GAAP Adjusted EBITDAFor Q3 2020, Alimera reported a net loss of approximately $(0.6)million, compared to a net loss of $(3.1) million for Q3 2019. Adjusted EBITDA, a non-GAAP financial measure defined below, was approximately $1.4 million for Q3 2020, an improvement of approximately $1.9million compared to negative Adjusted EBITDA of approximately $0.5 million for Q3 2019.

Net Loss per ShareBasic and diluted net loss per share for Q3 2020 was $(0.12). This compares to basic and diluted net loss per share for Q3 2019 of $(0.66). (The per share amounts in this press release reflect the impact from Alimeras one-for-15 reverse stock split in November 2019.)

Cash and Cash EquivalentsAs of September 30, 2020, Alimera had cash and cash equivalents of approximately $11.3million, compared to $9.4 million as of December 31, 2019 and $13.5 million as of June 30, 2020. The sequential decrease in cash of $2.2 million from Q2 2020 reflects the impact of lower Q2 2020 revenue on working capital in 2020 and the planned one-time build-up of inventory for the transition of Alimeras component manufacturing to the United States and related transition expenses.

Definition of Non-GAAP Financial MeasureFor purposes of this press release, Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains (losses) from foreign currency exchange transactions and severance expenses. Please refer to the sections of this press release entitled Non-GAAP Financial Measure and Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA.

Conference Call to Be Held October 29, 2020Management will host a conference call at 9:00 AM ET on Thursday, October 29, 2020, to review financial results and provide an update on corporate developments. Following managements formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast which is also available through the companys website.

A webcast replay of the call will be available approximately one hour after the end of the call through January 29, 2021. The replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10149051. The telephonic replay will be available until November 12, 2020.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measure

This press release contains a discussion of Adjusted EBITDA, a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimeras operating performance. Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three and nine months ended September 30, 2020 and 2019 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled Reconciliation of GAAP Net Loss to non-GAAP Adjusted EBITDA. GAAP net loss is the most directly comparable GAAP financial measure to Adjusted EBITDA.

Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies.

The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimeras financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure.

About ILUVIEN

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Australia, Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is indicated in 17 European countries for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and in 16 European countries for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see https://iluvien.com/#isi.

Forward Looking Statements

This press release contains, and the remarks by Alimeras officers on the conference call may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimeras expectations with respect to its strategy to retain its work force through the COVID-19 pandemic to continue to drive revenue, its ability to continue to deliver positive adjusted EBITDA, its ability to continue investing in ILUVIEN and expanding geographically, its ability to position ILUVIEN as the preferred first-line treatment for DME through the NEW DAY Study and the ability of new partners to make ILUVIEN available in additional countries. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change them, and could cause actual results to differ materially from those projected in the forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, continuing risks relating to the COVID-19 pandemic that could (a) reverse the current trends in Alimeras revenues and Adjusted EBITDA, due to increased COVID-19 cases in certain states within the U.S. and in Alimeras international markets that have resulted or may again result in reduced access to medical facilities for patient visits with their physicians and continuing concerns of patients with diabetes who may be unwilling to visit their physicians in person (even if otherwise permitted) due to their fear of contracting COVID-19, (b) adversely affect Alimeras ability to maintain its work force and (c)limit Alimeras ability to continue investing in ILUVIEN and expanding geographically. Other meaningful factors that could cause actual results to differ include (i) risks associated with conducting the NEW DAY study during a pandemic and other risks of such a study, including the risk that the results may not meet Alimeras expectations that it will position ILUVIEN as the preferred first-line treatment for DME, and (ii) regulatory and business risks in the countries in which Alimeras new partners are or will be seeking proper authorization for the sale of ILUVIEN. Other factors are discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Alimeras Annual Report on Form 10-K for the year ended December 31, 2019 and Alimeras Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with the Securities and Exchange Commission (SEC) and are available on the SECs website at http://www.sec.gov. Applicable risk factors will also be described in those sections of Alimeras Quarterly Report on Form 10-Q for the third quarter of 2020, to be filed with the SEC soon.

The forward-looking statements in this press release speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether due to new information, future events or otherwise.

For investor inquiries: For media inquiries:Scott Gordon Jules Abrahamfor Alimera Sciences for Alimera Sciencesscottg@coreir.com julesa@coreir.com

ALIMERA SCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)

September30, December31, 2020 2019 (unaudited) CURRENT ASSETS: Cash and cash equivalents $ 11,254 $ 9,426 Restricted cash 32 33 Accounts receivable, net 15,628 19,331 Prepaid expenses and other current assets 3,177 2,565 Inventory 2,522 1,390 Total current assets 32,613 32,745 NON-CURRENT ASSETS: Property and equipment, net 1,582 940 Right of use assets, net 791 1,107 Intangible asset, net 13,327 14,783 Deferred tax asset 767 734 TOTAL ASSETS $ 49,080 $ 50,309 CURRENT LIABILITIES: Accounts payable $ 5,356 $ 7,077 Accrued expenses 3,475 4,716 Notes payable 1,185 ? Finance lease obligations 219 255 Total current liabilities 10,235 12,048 NON-CURRENT LIABILITIES: Note payable, net of discount 42,459 38,658 Finance lease obligations ? less current portion 452 94 Other non-current liabilities 3,567 3,954 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS? DEFICIT: Preferred stock: Series A Convertible Preferred Stock 19,227 19,227 Series C Convertible Preferred Stock 9,474 11,117 Common stock 51 50 Additional paid-in capital 352,728 350,117 Common stock warrants 3,707 3,707 Accumulated deficit (391,932 ) (387,570 )Accumulated other comprehensive loss (888 ) (1,093 )TOTAL STOCKHOLDERS? DEFICIT (7,633 ) (4,445 )TOTAL LIABILITIES AND STOCKHOLDERS? DEFICIT $ 49,080 $ 50,309

ALIMERA SCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE AND NINE MONTHS ENDED SEPTEMBER30, 2020 AND 2019(in thousands, except share and per share data)

Three Months Ended Nine Months Ended September30, September30, 2020 2019 2020 2019 (unaudited)NET REVENUE $ 12,473 $ 12,850 $ 37,046 $ 36,595 COST OF GOODSSOLD, EXCLUDING (1,537 ) (1,579 ) (4,949 ) (4,353 )DEPRECIATION ANDAMORTIZATIONGROSS PROFIT 10,936 11,271 32,097 32,242 RESEARCH,DEVELOPMENT AND 2,469 2,761 7,162 8,322 MEDICAL AFFAIRSEXPENSESGENERAL ANDADMINISTRATIVE 2,619 3,121 8,775 10,189 EXPENSESSALES ANDMARKETING 4,764 6,437 14,818 18,458 EXPENSESDEPRECIATION AND 677 668 2,016 1,974 AMORTIZATIONOPERATING 10,529 12,987 32,771 38,943 EXPENSESNET INCOME (LOSS) 407 (1,716 ) (674 ) (6,701 )FROM OPERATIONSINTEREST EXPENSE (1,285 ) (1,232 ) (3,928 ) (3,696 )AND OTHERUNREALIZEDFOREIGN CURRENCY 267 (115 ) 295 (135 )GAIN (LOSS), NETNET LOSS BEFORE (611 ) (3,063 ) (4,307 ) (10,532 )TAXESPROVISION FOR (7 ) (77 ) (55 ) (409 )TAXESNET LOSS $ (618 ) $ (3,140 ) $ (4,362 ) $ (10,941 )NET LOSS PERCOMMON SHARE ? $ (0.12 ) $ (0.66 ) $ (0.87 ) $ (2.31 )Basic and dilutedWEIGHTED AVERAGECOMMON SHARES 5,068,701 4,733,484 5,026,905 4,727,472 OUTSTANDING ?Basic and diluted

ALIMERA SCIENCES, INC.CONSOLIDATING STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED SEPTEMBER30, 2020 AND 2019(in thousands)

Three Months Ended Three Months Ended September 30, 2020 September 30, 2019 U.S. International Other Consolidated U.S. International Other Consolidated (unaudited)NET REVENUE $ 6,962 $ 5,511 $ ? $ 12,473 $ 8,692 $ 4,158 $ ? $ 12,850 COST OF GOODSSOLD, EXCLUDING (746 ) (791 ) ? (1,537 ) (1,001 ) (578 ) ? (1,579 )DEPRECIATION ANDAMORTIZATIONGROSS PROFIT 6,216 4,720 ? 10,936 7,691 3,580 ? 11,271 RESEARCH,DEVELOPMENT AND 1,560 861 48 2,469 1,573 1,100 88 2,761 MEDICAL AFFAIRSEXPENSESGENERAL ANDADMINISTRATIVE 1,952 475 192 2,619 2,032 768 321 3,121 EXPENSESSALES AND 3,461 1,226 77 4,764 4,502 1,840 95 6,437 MARKETING EXPENSESDEPRECIATION AND ? ? 677 677 ? ? 668 668 AMORTIZATIONOPERATING EXPENSES 6,973 2,562 994 10,529 8,107 3,708 1,172 12,987 SEGMENT (LOSS)INCOME FROM (757 ) 2,158 (994 ) 407 (416 ) (128 ) (1,172 ) (1,716 )OPERATIONSOTHER INCOME AND ? ? (1,018 ) (1,018 ) ? ? (1,347 ) (1,347 )EXPENSES, NETNET LOSS BEFORE $ (611 ) $ (3,063 )TAXES

ALIMERA SCIENCES, INC.CONSOLIDATING STATEMENTS OF OPERATIONSFOR THE NINE MONTHS ENDED SEPTEMBER30, 2020 AND 2019(in thousands)

Nine Months Ended Nine Months Ended September 30, 2020 September 30, 2019 U.S. International Other Consolidated U.S. International Other Consolidated (unaudited)NET REVENUE $ 17,449 $ 19,597 $ ? $ 37,046 $ 22,778 $ 13,817 $ ? $ 36,595 COST OF GOODSSOLD, EXCLUDING (1,928 ) (3,021 ) ? (4,949 ) (2,494 ) (1,859 ) ? (4,353 )DEPRECIATION ANDAMORTIZATIONGROSS PROFIT 15,521 16,576 ? 32,097 20,284 11,958 ? 32,242 RESEARCH,DEVELOPMENT AND 4,580 2,418 164 7,162 4,629 3,361 332 8,322 MEDICAL AFFAIRSEXPENSESGENERAL ANDADMINISTRATIVE 5,867 2,250 658 8,775 6,116 2,876 1,197 10,189 EXPENSESSALES AND 10,948 3,618 252 14,818 12,760 5,324 374 18,458 MARKETING EXPENSESDEPRECIATION AND ? ? 2,016 2,016 ? ? 1,974 1,974 AMORTIZATIONOPERATING EXPENSES 21,395 8,286 3,090 32,771 23,505 11,561 3,877 38,943 SEGMENT (LOSS)INCOME FROM (5,874 ) 8,290 (3,090 ) (674 ) (3,221 ) 397 (3,877 ) (6,701 )OPERATIONSOTHER INCOME AND ? ? (3,633 ) (3,633 ) ? ? (3,831 ) (3,831 )EXPENSES, NETNET LOSS BEFORE $ (4,307 ) $ (10,532 )TAXES

RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURESGAAP NET INCOME OR LOSS TO NON-GAAP ADJUSTED EBITDA(in thousands)

Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (unaudited)GAAP NET LOSS $ (618 ) $ (3,140 ) $ (4,362 ) $ (10,941 )Adjustments to net loss: Interest expense and other 1,285 1,232 3,928 3,696 Provision for taxes 7 77 55 409 Depreciation and amortization 677 668 2,016 1,974 Stock-based compensation 317 504 1,074 1,903 expensesUnrealized foreign currency (267 ) 115 (295 ) 135 exchange (gains) lossesSeverance expenses ? 23 ? 198 NON-GAAP ADJUSTED EBITDA $ 1,401 $ (521 ) $ 2,416 $ (2,626 )